Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era

References

• KonstantinidesSVTorbickiAAgnelliG2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolismEur Heart J2014353033306925173341
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAmerican College of Chest PhysiciansAntithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest2012141e419Se494S22315268
   PubMed Web of Science ®Google Scholar
• AgenoWGallusASWittkowskyACrowtherMHylekEMPalaretiGOral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest2012141e44Se88S22315269
   PubMed Web of Science ®Google Scholar
• EikelboomJWWeitzJINew anticoagulantsCirculation20101211523153220368532
   PubMed Web of Science ®Google Scholar
• CarrierMRodgerMAWellsPSRighiniMLe GalGResidual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysisJ Thromb Haemost201191119112521382171
   PubMed Web of Science ®Google Scholar
• DouketisJTosettoAMarcucciMPatient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of d-dimer testing to assess recurrence risk after unprovoked venous thromboembolismAnn Intern Med201015352353120956709
   PubMed Web of Science ®Google Scholar
• RodgerMAKahnSRWellsPSIdentifying unprovoked throm-boembolism patients at low risk for recurrence who can discontinue anticoagulant therapyCMAJ200817941742618725614
   PubMed Web of Science ®Google Scholar
• EichingerSHeinzeGJandeckLMKyrlePARisk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction modelCirculation20101211630163620351233
   PubMed Web of Science ®Google Scholar
• TosettoAIorioAMarcucciMPredicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH)J Thromb Haemost2012101019102522489957
   PubMed Web of Science ®Google Scholar
• BatesSMGreerIAMiddeldorpSVeenstraDLPrabulosAMVandvikPOVTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest2012141e691Se736S22315276
   PubMed Web of Science ®Google Scholar
• The EINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med20103632499251021128814
   PubMed Web of Science ®Google Scholar
• The EINSTEIN–PE InvestigatorsOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med20123661287129722449293
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAAMPLIFY InvestigatorsOral apixaban for the treatment of acute venous thromboembolismN Engl J Med201336979980823808982
   PubMed Web of Science ®Google Scholar
• The Hokusai-VTE InvestigatorsEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med20133691406141523991658
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med20093612342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKGoldhaberSZRE-COVER II Trial InvestigatorsTreatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisCirculation201412976477224344086
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAAMPLIFY-EXT InvestigatorsApixaban for extended treatment of venous thromboembolismN Engl J Med201336869970823216615
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKRE-SONATE Trial InvestigatorsExtended use of dabigatran, warfarin, or placebo in venous thromboembolismN Engl J Med201336870971823425163
   PubMed Web of Science ®Google Scholar
• KakkosSKKirkilesisGITsolakisIAEditor’s Choice – efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trialsEur J Vasc Endovasc Surg20144856557524951377
   PubMed Web of Science ®Google Scholar
• PrinsMHLensingAWBauersachsREINSTEIN InvestigatorsOral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThromb J2013112124053656
   PubMedGoogle Scholar
• SiegalDMCrowtherMAAcute management of bleeding in patients on novel oral anticoagulantsEur Heart J20133448949823220847
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMEuropean Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEuropace20131562565123625942
   PubMed Web of Science ®Google Scholar
• ZahirHMatsushimaNHalimABEdoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsThromb Haemost201210816617522628060
   PubMed Web of Science ®Google Scholar
• Bayer Pharma AGXarelto^® (rivaroxaban) Summary of Product Characteristics2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed June 9, 2015
   Google Scholar
• Bristol-Myers Squibb PfizerEliquis^® (apixaban) Summary of Product Characteristics2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed April 28, 2015
   Google Scholar
• Boehringer Ingelheim International GmbHPradaxa^® (dabigatran etexilate) Summary of Product Characteristics2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfAccessed April 28, 2015
   Google Scholar
• BlannADLipGYLaboratory monitoring of the non-vitamin K oral anticoagulantsJ Am Coll Cardiol2014641140114225212649
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals IncXarelto^® (rivaroxaban) Prescribing Information2015 Available from: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdfAccessed June 9, 2015
   Google Scholar
• Bristol-Myers Squibb Company, Pfizer IncEliquis^® (apixaban) Prescribing Information2014 Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdfAccessed April 28, 2015
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals IncPradaxa^® (dabigatran etexilate) Prescribing Information2015 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdfAccessed April 28, 2015
   Google Scholar
• SchieleFvan RynJCanadaKA specific antidote for dabigatran: functional and structural characterizationBlood20131213554356223476049
   PubMed Web of Science ®Google Scholar
• LuGDeGuzmanFRHollenbachSJA specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation Factor XaNat Med20131944645123455714
   PubMed Web of Science ®Google Scholar
• PollackCVJrReillyPABernsteinRDesign and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatranThromb Haemost201511419820526020620
   PubMed Web of Science ®Google Scholar
• MikkaichiTYoshigaeYMasumotoHEdoxaban transport via P-glycoprotein is a key factor for the drug’s dispositionDrug Metab Dispos20144252052824459178
   PubMed Web of Science ®Google Scholar
• MerliGJHollanderJELefebvrePRates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxabanHosp Pract19952015438593
   Google Scholar
• AminABrunoATrocioJLinJLingohr-SmithMReal-world medical cost avoidance when new oral anticoagulants are used versus warfarin for venous thromboembolism in the United StatesClin Appl Thromb Hemost Epub2015519
   Web of Science ®Google Scholar
• BamberLWangMYPrinsMHPatient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosisThromb Haemost201311073274123846019
   PubMed Web of Science ®Google Scholar
• PrinsMBamberLCanoSWangMLensingABauersachsRPatient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolismBlood2012120 Abstract 1163
   PubMedGoogle Scholar
• LalibertéFBookhartBKNelsonWWImpact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolismPatient2013621322423857628
   PubMedGoogle Scholar
• CitroRPanzaABottiglieriGSurgical treatment of impending paradoxical embolization associated with pulmonary embolism in a patient with heterozygosis of Factor V LeidenJ Cardiovasc Med (Hagerstown)20131474574720639767
   PubMed Web of Science ®Google Scholar
• CookRMRondinaMTHortonDJRivaroxaban for the long-term treatment of spontaneous ovarian vein thrombosis caused by Factor V Leiden homozygosityAnn Pharmacother2014481055106024798316
   PubMed Web of Science ®Google Scholar
• JukicITitlicMTonkicARosenzweigDCerebral venous sinus thrombosis as a recurrent thrombotic event in a patient with heterozygous prothrombin G20210A genotype after discontinuation of oral anticoagulation therapy: how long should we treat these patients with warfarin?J Thromb Thrombolysis200724778017245631
   PubMed Web of Science ®Google Scholar
• KimDILeeBBNohSIConservative management of superior mesenteric and portal vein thrombosis associated with protein C and S deficiencyInt Angiol1997162352389543219
   PubMed Web of Science ®Google Scholar
• KshatriyaSVillarrealDLiuKAngina pectoris in a patient with protein C deficiency and deep vein thrombosis: thrombus versus myxoma?Catheter Cardiovasc Interv20127929129321523888
   PubMed Web of Science ®Google Scholar
• DumkowLEVossJRPetersMJenningsDLReversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasmaAm J Health Syst Pharm2012691646165022997117
   PubMed Web of Science ®Google Scholar
• JavedaniPPHorowitzBZClarkWMLutsepHLDabigatran etexilate: management in acute ischemic strokeAm J Crit Care20132216917623455868
   PubMed Web of Science ®Google Scholar
• MolinaMHillardVHFeketeRIntracranial hemorrhage in patient treated with rivaroxabanHematol Rep20146528324711920
   PubMedGoogle Scholar
• LakatosBStoeckleMElziLBattegayMMarzoliniCGastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virusSwiss Med Wkly2014144w1390624452338
   PubMed Web of Science ®Google Scholar
• GonzvaJPatricelliRLignacDSpontaneus splenic rupture in a patient treated with rivaroxabanAm J Emerg Med20143295024612597
   PubMed Web of Science ®Google Scholar
• OnodaSMitsufujiHYanaseNDrug interaction between gefitinib and warfarinJpn J Clin Oncol20053547848216006576
   PubMed Web of Science ®Google Scholar
• SaifMWWasifNInteraction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancerJOP2008973974318981557
   PubMedGoogle Scholar